EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Insights on hospitalisations from the phase 3a COMBINE 1–3 trials of once-weekly IcoSema in individuals with type 2 diabetes: a post hoc analysis

Francesco Giorgino, Raluca Maltesen, Laura Pletsch-Borba, Cathrine Scavenius, Ryo Suzuki, André G. D. Vianna, Athena Philis-Tsimikas

Metabologia · 2026

DOI: 10.1007/s44357-026-00025-3 ↗
AbstractBibliografische Angaben

Abstract

Abstract Aims/hypothesis The COMBINE phase 3a trials evaluated the efficacy and safety of IcoSema, a once-weekly combination therapy of basal insulin icodec and semaglutide (a glucagon-like peptide-1 [GLP-1] analogue) in adults with type 2 diabetes. This post hoc analysis of the COMBINE 1–3 trials evaluated the impact of IcoSema during and around hospitalisation. Methods Across the COMBINE 1–3 trials, 2637 adults with type 2 diabetes received IcoSema or a comparator (insulin icodec; semaglutide 1.0 mg; or insulin glargine U100 + insulin aspart). Hospitalisation data were recorded through adverse event reports as part of safety monitoring. Upon trial completion, available data were used to assess: overall number and duration of hospitalisations; treatment discontinuation; IcoSema dose; HbA 1c levels; self-measured blood glucose levels; and number of hypoglycaemia episodes before, during and after hospitalisation. Results Across trials, 106/1325 participants receiving IcoSema and 92/1312 participants receiving a comparator were hospitalised. Median duration of hospital stay was 4.0 days with IcoSema and 5.0 days with comparators. Most hospitalised participants completed their trial without permanently discontinuing treatment (IcoSema 96.2%; comparators 93.5%). Mean IcoSema dose remained fairly stable before and after hospitalisation. Numerical reductions in mean HbA 1c levels and generally stable self-measured blood glucose values were observed during and around hospitalisation in both treatment groups. Three participants receiving IcoSema and eight participants receiving a comparator reported clinically significant or severe hypoglycaemia during hospitalisation. Conclusions/interpretation Post hoc findings suggest that IcoSema did not affect hospitalisation incidence or duration, and IcoSema dosing remained stable before and after hospitalisation. Hospitalisation did not have a negative impact on glycaemic control, and the number of hypoglycaemia episodes with IcoSema was low during hospitalisation. Trial registration COMBINE 1: ClinicalTrials.gov, NCT05352815 (registered 24 April 2022); COMBINE 2: ClinicalTrials.gov, NCT05259033 (registered 10 February 2022); COMBINE 3: ClinicalTrials.gov, NCT05013229 (registered 13 August 2021).

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →